Stock Evaluator: Jiangsu Hengrui Pharmaceuticals Co.,Ltd (JHPCY)
Jiangsu Hengrui Pharmaceuticals Co.,Ltd JHPCY
$20.00
0.00
0.00%
August 19, 2026 9:30:02 AM
EST
Volume: 50
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
| DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Pharmaceuticals |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Jiangsu Hengrui Pharmaceuticals Co.,Ltd, a pharmaceutical company, researches, develops, manufactures, and commercializes medicines to address unmet clinical needs in China and internationally. The company develops medicines in the areas of oncology, metabolic and cardiovascular, immunological and respiratory, neuroscience, pain management, infectious, respiratory system, hematological, ophthalmology, and autoimmune and other diseases. The company was founded in 1970 and is headquartered in Lianyungang, China.
Financial Summary
| Share Statistics | JHPCY | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $45,123.3 | $674.5 | 93% |
|
| Shares Out (Mil) | 945.3 | 43.5 | 93% |
|
| Institutional Ownership | 49.8% | 84.6% | 25% |
|
| Float (Mil) | 3,583.5 | 47.3 | 97% |
|
| Beta | na | 0.71 | na |
|
| Avg Daily Volume (000s) | 2 | 290 | 9% |
|
| Price Change (52-week) |
na | 69.3% | na |
|
| Growth | JHPCY | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 1.3% | 6.7% | 21% |
|
| Net Income (5yr) | 2.6% | (1.4%) | 43% |
|
| EPS (5yr) | 2.1% | 15.0% | 34 |
|
| Dividends (5yr) | 2.3% | 0.0% | 53% |
|
| Cash Flow (5yr) | 23.7% | (15.0%) | 82% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | JHPCY | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $4,611 | $317 | 73% |
|
| Net Income (TTM) (Mil) | $1,137 | ($11) | 87% |
|
| EPS (TTM) | $0.173 | ($0.700) | 46% |
|
| Operating Cash Flow (TTM) (Mil) | $1,313 | ($6) | 84% |
|
| Net Cash Flow (TTM) (Mil) | $337 | $5 | 88% |
|
| Long-Term Debt (Q1) (Mil) | $6 | $6 | 25% |
|
| Enterprise Value (Q1) (Mil) | $45,478 | $536 | 91% |
|
| Valuation | JHPCY | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.80 | na |
|
| P/E | na | 17.1 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | JHPCY | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 85.8% | 68.1% | 92% |
|
| Net Margin | 24.7% | (1.4%) | 83% |
|
| ROA | 11.8% | (24.1%) | 90% |
|
| ROE | 12.9% | (21.0%) | 65% |
|
| Liabilities to Assets | 8.2% | 32.3% | 5% |
|
| F-Score | na | 3 | na |
|
Jiangsu Hengrui Pharmaceuticals Co.,Ltd did not pass any screens on 9/4/2026.
